Joel Neal

Joel Neal

UNVERIFIED PROFILE

Are you Joel Neal?   Register this Author

Register author
Joel Neal

Joel Neal

Publications by authors named "Joel Neal"

Are you Joel Neal?   Register this Author

92Publications

2482Reads

34Profile Views

Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.

Lung Cancer 2019 Aug 3;134:42-45. Epub 2019 May 3.

Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.05.002DOI Listing
August 2019

Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".

Lung Cancer 2019 Aug 26. Epub 2019 Aug 26.

Stanford Cancer Institute, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA, 94305, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.08.020DOI Listing
August 2019

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.

Lung Cancer 2019 Jul 15;133:144-150. Epub 2019 May 15.

Stanford Cancer Institute, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA, 94304, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.05.015DOI Listing
July 2019

Osimertinib for -Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.

Oncologist 2019 Jun 20;24(6):836-843. Epub 2018 Aug 20.

Division of Oncology, Stanford University School of Medicine, Stanford, California, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0264DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656518PMC
June 2019

Increased Galectin-1 Expression in Thymic Epithelial Tumors.

Clin Lung Cancer 2019 May 21;20(3):e356-e361. Epub 2018 Dec 21.

Department of Radiation Oncology, Stanford University School of Medicine Stanford Cancer Institute, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.005DOI Listing
May 2019

Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis.

J Thorac Oncol 2019 Apr;14(4):e75-e77

Department of Medical Oncology, Stanford Cancer Institute, Stanford, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.030DOI Listing
April 2019

Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer.

J Thorac Oncol 2019 Feb 11;14(2):e21-e24. Epub 2018 Sep 11.

Department of Medical Oncology, Stanford Cancer Institute, Stanford, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.08.2030DOI Listing
February 2019

Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam.

J Glob Oncol 2018 11;4:1-9

Kim-Son H. Nguyen, Palo Alto Medical Foundation, Mountain View; Henning Stehr, Li Zhou, Heather A. Wakelee, Maximilian Diehn, and Joel W. Neal, Stanford University School of Medicine, Stanford; Anh-Hoa Nguyen, AK Research Group, Redwood City, CA; Pham Nhu Hiep, Nguyen Van Cau, Hue Central Hospital; Phan Canh Duy, Hue University School of Medicine and Pharmacy, Hue, Vietnam; and Richard Thorp, BioreclamationIVT, Chestertown, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.18.00086DOI Listing
November 2018

Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.

Clin Lung Cancer 2018 09 19;19(5):e581-e588. Epub 2018 Apr 19.

Department of Radiation Oncology, Stanford Cancer Institute, Stanford, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.04.003DOI Listing
September 2018

Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer.

J Clin Oncol 2018 09 25;36(26):2677-2679. Epub 2018 Jun 25.

Jeffrey R. Zweig and Joel W. Neal, Stanford University School of Medicine, Stanford, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.8554
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.8554DOI Listing
September 2018

Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations.

Lung Cancer 2018 08 15;122:187-191. Epub 2018 Jun 15.

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.06.019DOI Listing
August 2018

Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma.

J Thorac Cardiovasc Surg 2017 12 1;154(6):2092-2099.e2. Epub 2017 Aug 1.

Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford, Calif; Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtcvs.2017.07.034DOI Listing
December 2017

Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?

Am Soc Clin Oncol Educ Book 2017 ;37:e8-e15

From the Fox Chase Cancer Center, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University, Palo Alto, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_175524DOI Listing
November 2017

Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer.

Radiother Oncol 2017 11 19;125(2):338-343. Epub 2017 Aug 19.

Department of Radiation Oncology, Stanford University, USA; Stanford Cancer Institute, Stanford University School of Medicine, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2017.08.007DOI Listing
November 2017

Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.

Int J Radiat Oncol Biol Phys 2017 09 6;99(1):16-21. Epub 2017 May 6.

Department of Radiation Oncology, Stanford University, Stanford, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2017.04.041DOI Listing
September 2017

Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer.

Mol Diagn Ther 2017 08;21(4):431-436

Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40291-017-0275-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511778PMC
August 2017

The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer.

Cancer 2017 08 4;123(15):2798-2801. Epub 2017 May 4.

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30718DOI Listing
August 2017

Novel systemic therapy against malignant pleural mesothelioma.

Transl Lung Cancer Res 2017 Jun;6(3):295-314

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://tlcr.amegroups.com/article/view/13734/11624
Publisher Site
http://dx.doi.org/10.21037/tlcr.2017.06.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504105PMC
June 2017

ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.

J Thorac Oncol 2017 05 4;12(5):833-842. Epub 2017 Feb 4.

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.01.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402884PMC
May 2017

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

J Clin Oncol 2017 May 13;35(13):1403-1410. Epub 2017 Mar 13.

Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.9352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559893PMC
May 2017

Elusive Target of Angiogenesis in Small-Cell Lung Cancer.

J Clin Oncol 2017 04 6;35(12):1269-1271. Epub 2017 Feb 6.

Joel W. Neal and Heather A. Wakelee, Stanford University School of Medicine, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.6084DOI Listing
April 2017

Relationship between anti-depressant use and lung cancer survival.

Cancer Treat Res Commun 2017 29;10:33-39. Epub 2017 Jan 29.

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2017.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603309PMC
January 2017

Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.

Clin Ther 2016 Jul 29;38(7):1567-76. Epub 2016 Jun 29.

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2016.06.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985173PMC
July 2016

Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.

Clin Lung Cancer 2016 Mar 18;17(2):e17-21. Epub 2015 Dec 18.

Division of Medical Oncology, Stanford Hospital and Clinics, Stanford, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2015.12.001DOI Listing
March 2016

Pruritus as a Paraneoplastic Symptom of Thymoma.

J Thorac Oncol 2015 Nov;10(11):e110-2

*Division of Oncology, Department of Medicine, †Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California; ‡Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, California; §Stanford Thoracic Oncology, Stanford Health Care, Stanford, California; ¶Department of Dermatology, Stanford University School of Medicine, Stanford, California; ‖Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China; #Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; **Department of Pathology, ††Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California; ‡‡Division of Oncology, Department of Medicine, Ukiah Valley Rural Health Center, Ukiah, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000623DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720251PMC
November 2015

Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.

Am J Ophthalmol 2015 Oct 17;160(4):799-805.e1. Epub 2015 Jul 17.

Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajo.2015.07.012DOI Listing
October 2015

Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.

Lung Cancer 2015 Oct 30;90(1):1-7. Epub 2015 Jul 30.

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.07.016DOI Listing
October 2015

Management of Dermatologic Complications of Lung Cancer Therapies.

Curr Treat Options Oncol 2015 Oct;16(10):50

Department of Dermatology, Stanford University, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-015-0368-yDOI Listing
October 2015

Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.

Transl Lung Cancer Res 2015 Oct;4(5):639-41

1 Division of Hematology and Oncology, Stanford Hospital & Clinics, Stanford, CA, USA ; 2 Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.03.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630528PMC
October 2015

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.

Clin Lung Cancer 2015 Sep 31;16(5):366-73. Epub 2014 Dec 31.

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2014.12.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490141PMC
September 2015

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.

Lung Cancer 2015 Sep 22;89(3):280-6. Epub 2015 Jun 22.

Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.06.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613811PMC
September 2015

Rociletinib in EGFR-mutated non-small-cell lung cancer.

N Engl J Med 2015 Apr;372(18):1700-9

From Massachusetts General Hospital (L.V.S., R.S.H., J.L., Z.P.), Harvard Medical School (L.V.S., G.R.O., R.S.H., Z.P.), and Dana-Farber Cancer Institute (G.R.O.) - all in Boston; the Drug Development Department, Université Paris-Sud, Gustave Roussy Cancer Campus (J.-C.S.), and Institut Gustave Roussy (A.V.), Villejuif - both in France; the David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (J.W.G., E.B.G., M.A.M., S.N.), and Stanford Cancer Institute, Stanford University, Stanford (H.A.W., J.W.N.) - both in California; the Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit (S.M.G., C.G., A.J.W.); University of Texas M.D. Anderson Cancer Center, Houston (V.P.); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); the Medical University of Gdansk, Gdansk, Poland (R.D.); the University of Colorado (D.L.A., D.R.C.) and University of Colorado Cancer Center (R.C.D.) - both in Aurora; and Clovis Oncology, San Francisco (M.R., C.A.K., S.J.-T., S.L.M., A.R.A.), Boulder, CO (J.I., D.D.), and Cambridge, United Kingdom (L.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1413654DOI Listing
April 2015

Diffuse high intensity PD-L1 staining in thymic epithelial tumors.

J Thorac Oncol 2015 Mar;10(3):500-8

*Division of Oncology, Department of Internal Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA; †Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA; ‡Department of Pathology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA; and §Department of Health and Research Policy, Stanford University School of Medicine, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000429DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720257PMC
March 2015

Developing biomarker-specific end points in lung cancer clinical trials.

Nat Rev Clin Oncol 2015 Mar 23;12(3):135-46. Epub 2014 Dec 23.

Division of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 32 Fruit Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.222DOI Listing
March 2015

GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.

Anticancer Res 2015 Feb;35(2):669-76

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, U.S.A.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973531PMC
February 2015

Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.

Lung Cancer 2015 Jan 15;87(1):34-8. Epub 2014 Nov 15.

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.11.006DOI Listing
January 2015

Unicentric, multifocal Castleman disease of the mediastinum associated with cerebellitis.

Ann Thorac Surg 2015 Jan;99(1):e7-9

Division of Thoracic Surgery, Department of Surgery, Baylor College of Medicine, Houston, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2014.10.028DOI Listing
January 2015

Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours.

Nat Rev Clin Oncol 2014 Nov 7;11(11):627-8. Epub 2014 Oct 7.

Division of Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.171DOI Listing
November 2014

Review of the current targeted therapies for non-small-cell lung cancer.

World J Clin Oncol 2014 Oct;5(4):576-87

Kim-Son H Nguyen, Joel W Neal, Heather Wakelee, Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5306/wjco.v5.i4.576DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129523PMC
October 2014

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.

Nat Med 2014 May 6;20(5):548-54. Epub 2014 Apr 6.

1] Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA. [2] Department of Radiation Oncology, Stanford University, Stanford, California, USA. [3] Stanford Cancer Institute, Stanford University, Stanford, California, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nm.3519
Publisher Site
http://dx.doi.org/10.1038/nm.3519DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016134PMC
May 2014

Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.

Arch Pathol Lab Med 2014 Feb 28;138(2):171-4. Epub 2013 Jun 28.

From the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Cagle); the Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Drs Sholl and Lindeman); the Department of Laboratory Medicine, Grand River Hospital, Kitchener, Ontario, Canada (Dr Divaris); the Department of Pathology, James A. Haley Veterans' Hospital, Tampa, Florida (Dr Foulis); the Cancer Information Program, Cancer Care Ontario, Ontario, Canada (Ms Lee); the Department of Medicine, Division of Oncology, Stanford Cancer Center, Stanford, California (Dr Neal); the Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, Evanston, Illinois (Dr Nowak); and the Department of Hematology-Oncology, Palo Alto Medical Foundation, Mountain View, California (Dr Yu). Dr Alsabeh is in private practice, Beverly Hills, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2013-0232-CPDOI Listing
February 2014

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.

Cancer Discov 2013 Dec 26;3(12):1364-77. Epub 2013 Sep 26.

Departments of 1Pediatrics, 2Genetics, and 5Medicine-Oncology, 3Vincent Coates Mass Spectrometry Laboratory, Stanford University, Stanford; and 4Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Cancer Center, University of California Davis School of Medicine, Sacramento, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0183DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864571PMC
December 2013

Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond.

Transl Lung Cancer Res 2013 Oct;2(5):411-4

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2013.10.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367722PMC
October 2013

A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib.

J Natl Compr Canc Netw 2013 Apr;11(4):389-94

Department of Medicine, Division of Oncology, Division of Neuro-Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329611PMC
http://dx.doi.org/10.6004/jnccn.2013.0054DOI Listing
April 2013

A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.

J Thorac Oncol 2013 Feb;8(2):e17-8

Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31827690daDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552378PMC
February 2013

Aflibercept in lung cancer.

Expert Opin Biol Ther 2013 Jan 1;13(1):115-20. Epub 2012 Dec 1.

Stanford University/Stanford Cancer Institute, Department of Medicine (Oncology), Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2013.745847DOI Listing
January 2013

Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.

J Thorac Oncol 2012 Dec;7(16 Suppl 5):S385-6

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford Cancer Institute, Stanford, California 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31826df166DOI Listing
December 2012

MET inhibitors in combination with other therapies in non-small cell lung cancer.

Transl Lung Cancer Res 2012 Dec;1(4):238-53

Stanford University/Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA.

View Article

Download full-text PDF

Source
http://www.tlcr.org/article/view/621
Publisher Site
http://dx.doi.org/10.3978/j.issn.2218-6751.2012.10.08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367550PMC
December 2012

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.

Biologics 2012 25;6:337-45. Epub 2012 Sep 25.

Stanford Cancer Institute, Stanford University, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BTT.S26558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459550PMC
October 2012

Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.

J Clin Oncol 2012 Jun 16;30(18):2280-2. Epub 2012 Apr 16.

Stanford Cancer Institute, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.41.0860DOI Listing
June 2012

Current management of small cell lung cancer.

Clin Chest Med 2011 Dec 28;32(4):853-63. Epub 2011 Sep 28.

Stanford Cancer Institute, Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccm.2011.07.002DOI Listing
December 2011

Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer.

J Thorac Oncol 2011 Nov;6(11 Suppl 4):S1797-8

Stanford University/Stanford Cancer Center, Stanford, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.JTO.0000407562.07029.52DOI Listing
November 2011

One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancer.

Clin Cancer Res 2011 Feb 16;17(4):638-9. Epub 2010 Dec 16.

Stanford Cancer Center, Stanford, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-3081DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045701PMC
February 2011

The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer.

Authors:
Joel W Neal

Future Oncol 2010 Dec;6(12):1827-32

Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.10.156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042878PMC
December 2010

AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer.

Curr Opin Mol Ther 2010 Aug;12(4):487-95

Stanford University Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA.

View Article

Download full-text PDF

Source
August 2010

Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh.

Curr Treat Options Oncol 2010 Jun;11(1-2):36-44

Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-010-0120-6DOI Listing
June 2010

Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.

Nat Rev Clin Oncol 2010 Feb;7(2):71-2

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2009.191DOI Listing
February 2010

First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.

Clin Adv Hematol Oncol 2010 Feb;8(2):119-26

Dana-Farber/Partners CancerCare Hematology and Oncology Program, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
February 2010

Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells.

Blood 2003 Sep 8;102(5):1771-8. Epub 2003 May 8.

Department of Microbiology-Immunology, Northwestern University Medical School, 303 E. Chicago Ave, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2002-11-3551DOI Listing
September 2003

A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts.

J Biol Chem 2003 May 21;278(19):17246-54. Epub 2003 Feb 21.

Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M300528200DOI Listing
May 2003

Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells.

J Biol Chem 2002 Dec 25;277(51):49776-81. Epub 2002 Sep 25.

Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Avenue, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M207913200DOI Listing
December 2002